How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward
Journal: Journal of Addiction Medicine and Therapeutic Science (Vol.3, No. 1)Publication Date: 2017-10-24
Authors : Nobue Kitanaka Junichi Kitanaka F Scott Hall Satoshi Okumura Tomoyuki Sakamoto George R Uhl; Motohiko Takemura;
Page : 016-023
Keywords : Methamphetamine; Drug addiction; Reward; Histaminergic system; Metoprine; Histamine N-methyltransferase;
Abstract
Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1]. METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2- 4]. Acutely METH releases dopamine from synaptic terminals through multiple actions that include inducing reverse transport of dopamine via the dopamine transporter (DAT), impairing the function of the vesicular monoamine transporter-2 (VMAT2), leading to increased cytoplasmic dopamine concentrations, and inhibition of monoamine oxidase [5-8]. Moreover, these changes contribute to the production of oxidative metabolites, metabolic impairments, oxidative damage to dopamine terminals, and depletion of tissue dopamine levels [9-11]. METH and related drugs consequently produce broad effects on the central nervous system both acutely and chronically [12-14].
Other Latest Articles
- Substance Use and Relationship Functioning: A Parallel Process
- Substance Use among Adolescents in Spain: A Brief Report
- PTSD and Intimate Partner Violence: Clinical Considerations and Treatment Options
- An Examination of the Relationship between Socio-epidemiologic Factors and Positive Workplace Drug Tests in the United States
- Time of Death Relative to Alcohol Use: Application of Brain: blood Ratios and Gastric Ethanol
Last modified: 2018-09-06 14:19:11